News Napp launches Neulasta biosimilar in UK Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following
Oncology Has the NHS joined the biosimilars revolution? Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Clark, Napp’s director of biosimilars.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
